Phosphopeptide mapping of plexiform lesions in pulmonary arterial hypertension
Phosphopeptide mapping of plexiform lesions in pulmonary arterial hypertension
批准号:
8211870
负责人:
LAWRENCE S. ZISMAN
金额:
$7.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-30 至 2013-08-31
关键词:
AddressAlgorithmsBioinformaticsBlood VesselsBlood flowCellsChromatographyClinical TrialsDataDiseaseFamilyFreezingFrozen SectionsGoalsGrowthImatinibImmunoassayIncubatedInterventionKnowledgeLabelLeadLesionLungMapsMass Spectrum AnalysisMethodsMorbidity - disease rateOutputPathologyPatientsPeptidesPhasePhosphopeptidesPhosphoproteinsPhosphorylationPhosphorylation SitePhosphotransferasesProliferatingProtein AnalysisProtein IsoformsProtein-Serine-Threonine KinasesProteinsProteomicsProtocols documentationPublic HealthRare DiseasesReceptor Protein-Tyrosine KinasesRegulationRelative (related person)ResearchRoleSamplingSocietiesStructure of parenchyma of lungTechniquesTestingTissuesTyrosineTyrosine Kinase Inhibitorabstractingarterioleblood leadcandidate identificationcell growthexperiencehypertension controlinnovationinterestkinase inhibitorlaser capture microdissectionmortalitynanofluidicnew therapeutic targetnoveloncologyprotein aminoacid sequencepulmonary arterial hypertensiontherapeutic targettitanium dioxidevalidation studies
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Pulmonary Arterial Hypertension (PAH) is a rare disorder of the pulmonary vasculature associated with high morbidity and mortality. The pathology of the disease consists of plexiform lesions of proliferating cells which obstruct blood flow through the pulmonary arterioles. There is a growing interest in the use of kinase inhibitors to address this underlying pathology. However, very little is actually understood about the regulation of kinases in PAH, and the phosphoproteome in PAH has not yet been studied. This project will determine the phosphopeptide profile of lung tissue from subjects with idiopathic pulmonary arterial hypertension (iPAH) compared to controls. Titanium dioxide chromatography will be used to enrich for phosphopeptides which will then be identified by mass spectroscopy. A bioinformatics approach will be used to predict the kinases and/or kinase families most likely to be responsible for these increased phosphoproteins. The NetworKIN and other algorithms will be used for this purpose. The predictions of NetworkKIN will be tested in a subset of kinases by incubating the selected recombinantly expressed kinases with peptide microarrays that duplicate the peptide sequences of the candidate phosphorylation sites. The findings of the proteomic analysis will be validated by isolating protein from plexiform lesions with laser capture microdissection. The proteins will be analyzed with a novel nanofluidic immunoassay that can detect very small quantities of protein. The results of this study could identify new therapeutic targets for the treatment of iPAH and thereby benefit patients and society.
PUBLIC HEALTH RELEVANCE: Pulmonary Arterial Hypertension (PAH) is a rare disorder of the pulmonary blood vessels associated with high morbidity and mortality. The purpose of this project is to identify proteins that may be responsible for the abnormal growth of cells that block the blood vessels and lead to the disease. This project is relevant to public health because it could lead to new treatments for PAH. (End of Abstract)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel inhaled c-kit/PDGFR inhibitor for the treatment of asthma
-
批准号:9139718
-
项目类别:
-
资助金额:$33.73万
-
财政年份:2016
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
Phosphopeptide mapping of plexiform lesions in pulmonary arterial hypertension
-
批准号:8335485
-
项目类别:
-
资助金额:$7.25万
-
财政年份:2011
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
A novel JAK inhibitor for the treatment of pulmonary arterial hypertension
-
批准号:7801554
-
项目类别:
-
资助金额:$31.16万
-
财政年份:2010
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension
-
批准号:9326326
-
项目类别:
-
资助金额:$99.98万
-
财政年份:2010
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
A PDGFR inhibitor for the treatment of pulmonary arterial hypertension
-
批准号:7908994
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2010
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
EFFECT OF CARDIAC TISSUE SPECIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITION
-
批准号:6114166
-
项目类别:
-
资助金额:$3.22万
-
财政年份:1998
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
EFFECT OF CARDIAC TISSUE SPECIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITION
-
批准号:6275401
-
项目类别:
-
资助金额:$3.14万
-
财政年份:1997
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
CARDIAC RENIN/ANGIOTENSIN SYSTEM IN HEART FAILURE
-
批准号:2459874
-
项目类别:
-
资助金额:$8.36万
-
财政年份:1995
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
CARDIAC RENIN/ANGIOTENSIN SYSTEM IN HEART FAILURE
-
批准号:2211658
-
项目类别:
-
资助金额:$8.36万
-
财政年份:1995
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
CARDIAC RENIN/ANGIOTENSIN SYSTEM IN HEART FAILURE
-
批准号:6208188
-
项目类别:
-
资助金额:$5.41万
-
财政年份:1995
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
CARDIAC RENIN/ANGIOTENSIN SYSTEM IN HEART FAILURE
-
批准号:6043662
-
项目类别:
-
资助金额:$2.95万
-
财政年份:1995
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
CARDIAC RENIN/ANGIOTENSIN SYSTEM IN HEART FAILURE
-
批准号:2750258
-
项目类别:
-
资助金额:$1.81万
-
财政年份:1995
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
CARDIAC RENIN/ANGIOTENSIN SYSTEM IN HEART FAILURE
-
批准号:2211659
-
项目类别:
-
资助金额:$8.36万
-
财政年份:1995
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
CARDIAC RENIN/ANGIOTENSIN SYSTEM IN HEART FAILURE
-
批准号:6076381
-
项目类别:
-
资助金额:$6.55万
-
财政年份:1995
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
EFFECT OF CARDIAC TISSUE SPECIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITION
-
批准号:6304260
-
项目类别:
-
资助金额:$3.22万
-
财政年份:--
-
负责人:LAWRENCE S. ZISMAN
-
依托单位:
海外基金